Your Member Practices Are Leaving Millions in Denied Claims Unworked.
Independent practices deny at higher rates and appeal at lower rates than hospital systems. Not because the denials aren't winnable — because they don't have the staff.
Gold Card Qualification Tracker
Path to Regulatory Exemption
Track your network's progress toward the 90% PA approval threshold. Gold card status eliminates prior authorization entirely — transforming practice economics for biologic-heavy specialties.
Current Network PA Approval Rate
Distance from Gold Card: 8 percentage points
At current pace: Oct 2026 | With CoverageUnlocked: July 2026
Top Denial Categories Pulling You Below 90%
State Regulatory Environment
Regulatory Status
HB 3459 / HB 3812
Gold Card Threshold
90% PA Approval
Lookback Period
12-month lookback
Current Status
Active
Gold Card Economics
Gold card means your providers SKIP prior authorization entirely. For specialties where most medications require PA, this transforms practice economics — reducing administrative overhead by 8-12 hours/week per practice while accelerating biologic access by 30+ days.
Network-Wide Denial Analytics
The Denial Funnel
CIIC network scale: 45,000 annual claims across 64+ practices.
Claims Pipeline
Appeal Rate
5.0% of denials appealed
Overturn Rate
54% of appeals overturned
Recovery Opportunity
Claims Not Appealed
5,130
Out of 5,400 denials
Estimated Winnable
2,770
At 54% overturn rate (historical benchmark)
Revenue Left on Table / Quarter
$4.2M
At $1,520 average claim value
Annual Network Recovery Opportunity
$16.8M
Across 64+ practices if currently unappealed denials are systematically addressed.
Top Denying Payers by Network
Allergy & Immunology Denial Analysis
Specialty Denial Patterns
Biologics dominate allergy/immunology denials. Most require prior authorization. Denial patterns are predictable and winnable.
Top Denied Codes
J1459
IVIG (Immunoglobulin IV)
J0881
Dupixent (Dupilumab)
J2182
Nucala (Mepolizumab)
J0517
Xolair (Omalizumab)
95004
Allergy Testing
95117
Immunotherapy
Denial Rate Comparison
Biologic Denials
22%
vs 8% non-biologics
Non-Biologic Denials
8%
Average Biologic Cycle Time
44 days
From PA submission to first patient dose. This is a direct economic impact on practice revenue and patient outcomes.
PA Turnaround by Payer
Industry standard: 7 business days for PA decision. Only BCBS-TX meets this threshold. Systemic delays across UHC, Cigna, Aetna create clinical and financial impact for your member practices.
Practice-Level ROI Calculator
Recovery Impact Per Practice
Adjust provider count to see how recovery scales across your network.
Network Configuration
Standard Assumptions
Annual Incremental Recovery
$898K
Network-wide recovery above current baseline
Per-Provider ROI
$128K
/year
Staff Time Freed
148
hours/week (network)
Calculation Breakdown
Model assumes 54% overturn rate per OIG 2023 data, $1,520 average claim value for allergy/immunology specialty, and current 5% appeal rate baseline. Per-provider ROI divides network-wide recovery by provider count. Time savings estimate assumes ~15 minutes per appeal managed.
Biologic Access Timeline
The Cost of Delay
For biologics where most medications require prior authorization, the timeline gap is both a clinical and financial burden.
Current State: 44 Days
Day 0
PA submitted
Day 7
Info request
Day 14
Docs resubmitted
Day 21
Peer-to-peer call
Day 30
Approval/denial decision
Day 37
Specialty pharmacy order
Day 44
First patient dose
Total Duration
44 days
Approval Steps
6 touches
Patient Wait
44 days
With CoverageUnlocked: 10 Days
Day 0
Pre-check + PA submitted complete
Day 5
Approved
Day 10
First patient dose
Total Duration
10 days
Approval Steps
1 pre-check
Patient Wait
10 days
Annual Impact Per Practice
Time saved: 34 days per biologic initiation
For 20 biologic patients/month: 680 patient-days of delayed treatment eliminated annually
Staff efficiency: Pre-check eliminates 6 approval touchpoints and 4 back-and-forth cycles
Ready to Unlock Your Network's Recovery Potential?
Learn how specialty networks are recovering millions in denied claims while improving patient access and reducing administrative burden on member practices.
Contact Ned